Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244516 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL21458805 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL5250584 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL21069231 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL22631510 | 0.81 | EPHX1 (0.55) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL852267 | 0.80 | — | — | |
| SCHEMBL5246725 | 0.78 | EPHX1 (0.47) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL17433063 | 0.78 | TSHR (0.37) | MAPK1LMNASMN1; SMN2TSHRMEN1 | |
| SCHEMBL5251231 | 0.78 | EPHX1 (0.47) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL27700989 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11633492-B2 | Process for the synthesis of linker-drug vc-seco-DUBA | BYONDIS B.V. (NL) | 2023-04-25 | — | — | US | disclosed |
| EP-3713939-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO | BYONDIS BV (NL) | 2021-07-21 | — | — | EP | disclosed |
| US-20200368362-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | BYONDIS B.V. (NL) | 2020-11-26 | — | — | US | disclosed |
| EP-3713939-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO | Byondis B.V. (NL) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101850-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633492-B2 | Process for the synthesis of linker-drug vc-seco-DUBA | VCL, VCP, UBA2 | CHRNB2 3289/4885CHRNA4 3762/4885MAPK1 3044/4885 |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | CHRNB2 2192/4885CHRNA4 2983/4885MAPK1 2863/4885 |
| US-20200368362-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | UBE3A, VCP, VCL | CHRNB2 3163/4885CHRNA4 3043/4885MAPK1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.